Annals of surgical oncology
Audio Summaries

Comparison of 2015 and 2025 ATA Risk Stratification Systems for Predicting Recurrence in Papillary Thyroid Carcinoma

Aug 8, 2026

This study aimed to compare the predictive performance of the 2015 and 2025 American Thyroid Association (ATA) risk stratification systems for recurrence in patients with papillary thyroid carcinoma (PTC). The authors found that while both systems had comparable predictive performance, the 2025 system demonstrated improved risk discrimination by concentrating recurrence events primarily within the high-risk group, particularly affecting patients initially classified as intermediate risk.

Early-Onset Appendiceal Adenocarcinoma (Age < 50 Years): Temporal Trends in Case Proportions, Histologic Patterns, and Survival Outcomes From SEER, 2000-2023

Aug 8, 2026

This study investigates the clinicopathologic features and survival outcomes of early-onset appendiceal adenocarcinoma (diagnosed before age 50) using data from the SEER database between 2000 and 2023. The authors found that early-onset cases represent about 21.2% of appendiceal adenocarcinoma diagnoses and are associated with distinct demographic and histologic characteristics, while survival outcomes are primarily influenced by disease stage and tumor features rather than age alone. Additionally, the study highlights significant racial disparities in survival among early-onset patients, suggesting a need for further research in this area.

A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study

Aug 8, 2026

The authors aimed to develop a pathology-based model to predict postoperative recurrence and metastasis in patients with nonmetastatic clear cell renal cell carcinoma (ccRCC) and to assess the implications for adjuvant immunotherapy. By analyzing data from 2154 patients, they identified seven independent risk factors and constructed a prognostic model that effectively stratified patients, revealing that high-risk individuals significantly benefited from immune checkpoint inhibitors. This model outperformed current clinical trial criteria for adjuvant therapy, highlighting its potential to improve patient outcomes.

Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study

Aug 7, 2026

The authors aimed to determine whether graded histologic regression (GHR) of less than 50% after neoadjuvant chemotherapy could serve as an indicator for modifying adjuvant treatment in patients with locally advanced gastric cancer (LAGC). Their exploratory phase II study found that patients whose adjuvant regimen was modified based on GHR had significantly improved disease-free survival and overall survival compared to those who continued with the original regimen. The findings suggest that GHR < 50% may warrant changes in treatment, although further research is necessary to confirm these results.

De-escalation of Adjuvant EGFR-TKI in Stage IB EGFR-Mutated Non-small-cell Lung Cancer: A Real-World Study

Aug 7, 2026

The authors aimed to evaluate the long-term survival benefits of adjuvant epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with stage IB EGFR-mutated non-small-cell lung cancer (NSCLC). Their study found that while adjuvant EGFR-TKIs significantly improved disease-free and recurrence-free survival, there was no notable difference in overall survival, particularly in patients with smaller tumors or those without high-risk factors, suggesting that EGFR-TKIs may be unnecessary for certain subgroups.

Association of Cancer Center Designation with Multimodality Treatment, Perioperative Outcomes, and Survival among Older Adults with Pancreatic Ductal Adenocarcinoma

Aug 6, 2026

The authors aimed to investigate how cancer center designation affects treatment patterns, perioperative outcomes, and survival rates among older adults with stage I-III pancreatic ductal adenocarcinoma (PDAC). Their analysis of data from the SEER-Medicare database revealed that patients treated at NCI-designated centers experienced higher rates of multimodality treatment and significantly improved survival compared to those at non-designated centers. These findings underscore the critical role of specialized cancer centers in enhancing care for PDAC patients.

Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma

Aug 5, 2026

The authors aimed to evaluate the clinical and biological significance of CHMP3 in pancreatic ductal adenocarcinoma (PDAC) and its potential as a prognostic marker. They found that elevated CHMP3 expression correlates with poorer overall and disease-free survival, and its knockdown in cell lines reduced proliferation and increased sensitivity to gemcitabine. Despite these findings, the authors caution that the prognostic implications of CHMP3 may be confounded by treatment factors, necessitating further validation.

Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era

Aug 5, 2026

The authors aimed to characterize the real-world use of adjuvant systemic therapy (AST) in eligible renal cell carcinoma (RCC) patients following nephrectomy and to determine if treatment allocation aligns with established high-risk tumor characteristics. Their analysis of the SEER database revealed that while AST use increased from 13% in 2018 to 36% in 2022, only 18% of eligible patients received AST, with higher usage associated with adverse tumor features such as T4 stage, tumor grade 4, and N1-2 stage. Despite the increase in AST administration, it remained underutilized, particularly among high-risk patients.

Role of Palliative Cytoreductive Surgery for Patients with Incompletely Resectable Peritoneal Carcinomatosis from Lower Gastrointestinal Cancers

Aug 4, 2026

The authors investigate the role of palliative cytoreductive surgery (CRS) in patients with incompletely resectable peritoneal carcinomatosis due to lower gastrointestinal cancers, aiming to evaluate its impact on complication-free survival and overall survival. Their findings indicate that while palliative CRS can lead to improved obstruction-free and ascites-free survival in patients with low-grade tumors, high-grade histology is associated with significantly poorer outcomes. The study suggests that palliative surgical intervention may be beneficial for carefully selected patients with low-grade tumors.

Secondary Cytoreductive Surgery ± Hyperthermic Intraperitoneal Chemotherapy for Recurrent Colorectal Cancer Peritoneal Metastases

Aug 4, 2026

The authors aimed to evaluate the safety and oncologic benefit of secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) for patients with recurrent colorectal cancer peritoneal metastases (CRC-PM). Their findings indicate that secondary CRS±HIPEC is safe and associated with improved overall survival compared to initial CRS±HIPEC alone, suggesting it may be a viable option for well-selected patients experiencing recurrence.